News

Tetra Therapeutics has launched three pivotal Phase 2b/3 studies to continue to assess the safety and effectiveness of BPN14770, its investigational oral therapy for fragile X syndrome. The results, if they’re in agreement with previous positive data from a Phase 2 trial, will support Tetra’s application…

The International Fragile X Premutation Registry (IFXPR) — now enrolling — aims to accelerate research to better understand the impact on health of premutations in the gene associated with fragile X syndrome. One goal of the IFXPR, launched in the U.S. in 2020 and since going global,…

The University College of London (UCL) has licensed VSN16R, an investigational oral treatment for fragile X syndrome, to U.S.-based Lenire Biosciences. Although originally developed by UCL researchers for treating muscle spasticity in multiple sclerosis, recent preclinical data showed that VSN16R could lessen behavioral symptoms in a…

Katie Clapp said she thinks there were just five scientists researching fragile X syndrome when she attended her first conference about the disorder shortly after her son’s diagnosis in 1992. Today there are hundreds, if not thousands, of teams around the world working on the condition, which can…

Nonprofits, scientists, governmental organizations, and the rare disease drug development industry have long cited 7,000 as the average number of rare diseases in the world. But a new analysis shows there are as many as 10,867 rare diseases globally. And that…

Nova Mentis is teaming up with the University of Central Florida (UCF) Research Foundation to develop a new test that will use saliva samples to measure the levels of serotonin — a key neurotransmitter — in people with autism spectrum disorders (ASD), including fragile X syndrome, the company said…

Zygel, an experimental cannabidiol gel developed by Zynerba Pharmaceuticals to ease abnormal behaviors in people with fragile X syndrome, was well tolerated and effective, including in patients with severe disease, according to a new interim analysis of an open-label extension study. The poster, titled “Long-Term Safety and Sustained Efficacy…

Nova Mentis has received the green light from the U.S. Drug Enforcement Administration (DEA) to ship psilocybin (NM-1001) into Canada, moving it a step closer to being tested as a treatment for fragile X syndrome. Psilocybin arrived recently at the labs of the Toronto Institute of Pharmaceutical…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NeuroNascent’s NNI-351 for the treatment of fragile X syndrome. NNI-351, given orally, is able to penetrate the brain, where it has been shown to boost the proliferation and growth of immature progenitor cells into mature…

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to Neuronascent‘s investigational therapy NNI-351 for the treatment of fragile X syndrome (FXS). “With vast unmet need for novel therapies that can directly address pediatric FXS behavioral deficits, such as to improve education and social…